Surrogate endpoints for overall survival in lung cancer trials: a review.

about

Development of single nanometer-sized ultrafine oxygen bubbles to overcome the hypoxia-induced resistance to radiation therapy via the suppression of hypoxia-inducible factor‑1α.

P2860

Q47691251-5B6CE6D2-1017-4AB8-B97D-406D7A0213F3

P2860

Surrogate endpoints for overall survival in lung cancer trials: a review.

Item

http://www.wikidata.org/entity/Q38841987

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Surrogate endpoints for overall survival in lung cancer trials: a review.

@en

type

Item

label

Surrogate endpoints for overall survival in lung cancer trials: a review.

@en

prefLabel

Surrogate endpoints for overall survival in lung cancer trials: a review.

@en

P1476

Surrogate endpoints for overall survival in lung cancer trials: a review.

@en

P2093

Franck Bonnetain

http://www.w3.org/2001/XMLSchema#string

Frédéric Fiteni

http://www.w3.org/2001/XMLSchema#string

Virginie Westeel

http://www.w3.org/2001/XMLSchema#string

P2860

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.

Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.

P304

447-454

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1316196

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28399678

http://www.w3.org/2001/XMLSchema#string

Surrogate endpoints for overall survival in lung cancer trials: a review.

about

P2860

P2860

Surrogate endpoints for overall survival in lung cancer trials: a review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698